Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-deri ved endothelial cell growth factor (PD-ECGF). We conducted immunohistochemi cal staining of dThdPase to assess correlation between its expression in ca ncer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherap y and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor a nd stromal cells. Survival curves significantly differed between stromal dT hdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining succes s of the combination therapy.